Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 1.75 mg Formulation, With Fasting and Postprandial Administration, in Male and Female Healthy Volunteers, Produced by Biolab Sanus Farmacêutica Ltda
Latest Information Update: 13 Jun 2018
At a glance
- Drugs Zolpidem (Primary)
- Indications Sleep disorders
- Focus Pharmacokinetics
- Sponsors Biolab Sanus Farmaceutica
- 07 Jun 2018 Status changed from not yet recruiting to completed.
- 13 Jul 2017 Planned End Date changed from 1 May 2017 to 1 Jan 2018.
- 13 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.